- Home
- PKE vs ALDX Comparison
PKE vs ALDX Comparison
Compare PKE & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKE
- ALDX
- Stock Information
- Founded
- PKE 1954
- ALDX 2004
- Country
- PKE United States
- ALDX United States
- Employees
- PKE N/A
- ALDX N/A
- Industry
- PKE Military/Government/Technical
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- PKE Industrials
- ALDX Health Care
- Exchange
- PKE Nasdaq
- ALDX Nasdaq
- Market Cap
- PKE 260.2M
- ALDX 160.8M
- IPO Year
- PKE N/A
- ALDX 2014
- Fundamental
- Price
- PKE $14.42
- ALDX $3.79
- Analyst Decision
- PKE
- ALDX Strong Buy
- Analyst Count
- PKE 0
- ALDX 2
- Target Price
- PKE N/A
- ALDX $9.50
- AVG Volume (30 Days)
- PKE 53.2K
- ALDX 959.9K
- Earning Date
- PKE 07-15-2025
- ALDX 07-31-2025
- Dividend Yield
- PKE 3.37%
- ALDX N/A
- EPS Growth
- PKE N/A
- ALDX N/A
- EPS
- PKE 0.29
- ALDX N/A
- Revenue
- PKE $62,026,000.00
- ALDX N/A
- Revenue This Year
- PKE N/A
- ALDX N/A
- Revenue Next Year
- PKE N/A
- ALDX N/A
- P/E Ratio
- PKE $50.59
- ALDX N/A
- Revenue Growth
- PKE 10.75
- ALDX N/A
- 52 Week Low
- PKE $11.96
- ALDX $1.14
- 52 Week High
- PKE $15.57
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- PKE 56.01
- ALDX 76.85
- Support Level
- PKE $13.53
- ALDX $2.95
- Resistance Level
- PKE $14.04
- ALDX $3.29
- Average True Range (ATR)
- PKE 0.29
- ALDX 0.27
- MACD
- PKE -0.02
- ALDX 0.11
- Stochastic Oscillator
- PKE 52.00
- ALDX 95.89
About PKE Park Aerospace Corp.
Park Aerospace Corp designs develop and manufactures engineered, advanced composite materials and composite structures and assemblies and low-volume tooling for the aerospace markets and prototype tooling for such structures and assemblies. Geographically, the company derives a majority of revenue from North America and also has a presence in a company operates its business in Asia and Europe. It offers advanced composite Prepregs for Aircraft Structures and Interiors, Sigma Strut and Alpha Strut.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.